Navigation Links
?EastGate Acquisitions Augments Its Sub-Micron Self-Nanoemulsifying Platform Technology
Date:8/18/2014

SALT LAKE CITY and TORONTO, Aug. 18 , 2014 /PRNewswire/ -- EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of novel formulations and alternative dosage forms of existing biologically active molecules, announces that it is augmenting its self-emulsifying sub-micron platform technology to include a broad spectrum of delivery options. The various technologies are applicable to the company's current pharmaceutical products in development and can also be employed as effective platforms for delivery of other biologically active compounds. The company recently expanded its new product development to include large molecules as active compounds that will address indications in diabetes, obesity and the overall metabolic syndrome.

The company's technology platform led to the development of several improved novel formulations and alternative dosage forms for delivery of known biologically active molecules. The technology utilizes EastGate's sub-micron self-emulsifying delivery vehicle and facilitates the creation of harmonized formulations with better drug absorption. The company's technological approaches have demonstrated robustness and resulted in diversification of the drug delivery products. The variety of developed dosage forms includes liquid spray or droplets, semi-solid, compressed tablets and capsules of different types.

The purpose of offering this spectrum of dosage forms is to provide patients with different treatment possibilities and bring products that will fit their lifestyle and improve patient's compliance.

Currently the company is working towards acquiring the licensing rights to develop and manufacture an intraoral insulin formulation. The intraoral insulin dosage forms under consideration are liquid and solid dosage forms, such as compressed tablet which can be deli vered to the mouth for intraoral absorption. 

"We have recognized the importance of expanding our sub-micron self-nanoemulsifying platform technology to include different dosage forms and delivery methods," says Anna Gluskin, EastGate's CEO. "The versatility of the sub-micron platform technology will continue to validate the company's sub-micron approach and provide a unique opportunity to offer different absorption-enhanced products to widen the target patient population," states Gluskin.

About EastGate Acquisitions Corporation

EastGate Acquisitions Corporation with locations in Salt Lake City, Utah and Toronto, Canada, is a pharmaceutical company aimed at utilizing drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules. The Company's model is based on a two-tier business approach that includes development of novel pharmaceutical products and innovative dietary supplements. Both pharmaceutical products and natural supplements are developed using highly effective contemporary technologies and demonstrated already proven usefulness in improvement of bioavailability and biological action of incorporated molecules. The Company's product candidates address various pharmaceutical markets, including neurological disorders, such as epilepsy and panic attacks, infectious diseases and diabetes. Our natural dietary supplements, also an integral part of our R&D program, include compositions for glucose regulations, urinary tract health improvement, enhanced vitamin delivery and skin conditions. EastGate is working to expand its current product portfolio through targeted investments in pharmaceutical research and development. We are working closely with clinicians and patient advocate groups worldwide to identify existing health issues where EastGa te's approach will be most beneficial for patient care. For more information, please visit the company's website at www.EastGatePharmaceuticals.com.

Cautionary statement on forward-looking information

All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbour" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.

The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by EastGate as of the date of such statements, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this news release, include those identified from time to time in the reports filed by EastGate with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Rose Perri 1-647-692-0652
Email: information@eastgatepharmaceuticals.com  
Text:  ESAQ to 87804


'/>"/>
SOURCE EastGate Acquisitions Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
2. Henry Schein Completes Three Acquisitions To Advance Strategic Plan
3. Hanger, Inc. Announces 2012 Year To Date Acquisitions Totaling $35.6 Million Of Annual Net Revenue
4. VWR International, LLC Expands European Portfolio With Acquisitions Of Labonord SAS And Switch BVBA
5. Hanger, Inc. Has Record Year In O&P Acquisitions:
6. Medbox, Inc. Commences Pursuit of Strategic Acquisitions
7. Allergans Global Dominance in Facial Injectables Challenged by Acquisitions and Partnership Agreements Among Competitors
8. Hanger Announces 2013 Year-To-Date Acquisitions Totaling $10 Million Of Annualized Net Revenue
9. Sanomedics Receives Financing for Working Capital and Acquisitions
10. Sleep Nation, Inc. Completes 43 Acquisitions
11. Acquisitions, Conference Participations, Court Rulings, and Product Deliveries - Research Report on Zoetis, Aegerion Pharmaceuticals, Edwards, Community Health Systems, and Air Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
Breaking Medicine News(10 mins):